Reports Q2 revenue $825, consensus $761.66M. “We were very pleased with our second quarter performance across all aspects of the business, including strong growth, exciting pipeline progress, and delivery of our business development strategy,” said Alexander Hardy, President and Chief Executive Officer of BioMarin (BMRN).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BMRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioMarin Expands Board with New Director Appointment
- PTC Therapeutics price target raised to $46 from $42 at Barclays
- BioMarin’s BMN 349: A Promising Step in Genetic Lung Condition Treatment
- 3 “Strong Buy” Value Stocks to Buy Now, 7/23/2025, According to Analysts